An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom

Alzheimer's and Dementia

Volumn 8, Issue 1, 2012, Pages 22-30

  Getsios, Dennis ^a   Blume, Steve ^a   Ishak, Khajak J ^b   MacLaine, Grant ^c   Hernández, Luis ^d,e  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b UNITED BIOSOURCE CORPORATION   (Canada)

^c EISAI CO LTD   (Japan)

^d United BioSource Corporation   (Colombia)

^e UNIVERSIDAD DE LOS ANDES   (Colombia)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Cost effectiveness; Donepezil; Early assessment

Indexed keywords

DONEPEZIL;

ALZHEIMER DISEASE; ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; EARLY DIAGNOSIS; ECONOMIC EVALUATION; HEALTH CARE COST; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; UNITED KINGDOM;

ALZHEIMER DISEASE; CAREGIVERS; COGNITION DISORDERS; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; FEMALE; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; INDANS; LONGITUDINAL STUDIES; MALE; NOOTROPIC AGENTS; PIPERIDINES; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; STATISTICS AS TOPIC;

EID: 84856011523     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2010.07.001     Document Type: Article

References (34)

1. M. Knapp, M. Prince, E. Albanese, S. Banerjee, S. Dhanasiri, and J.-L. Fernandez For Kings' College London and London School of Economics 2007 Alzheimer's Society, Gordon House London Available at: http://www.alzheimers. org.uk/site/scripts/download-info.php?fileID=2
2. D.L. Weimer, and M.A. Sager Early identification and treatment of Alzheimer's disease: social and fiscal outcomes Alzheimers Dement 5 2009 215 226
3. National Audit Office Improving services and support for people with dementia July 2007 The Stationery Office London Available at: http://www.nao.ork.uk
4. J. Birks Cholinesterase inhibitors for Alzheimer's disease Cochrane Database Syst Rev 2006 CD005593
5. R.A. Hansen, G. Gartlehner, A.P. Webb, L.C. Morgan, C.G. Moore, and D.E. Jonas Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis Clin Interv Aging 3 2008 211 225 (Pubitemid 352037861)
6. C. Green Modelling disease progression in Alzheimer's disease A review of modelling methods used for cost-effectiveness analysis Pharmacoeconomics 25 2007 735 750
7. J. Cohen, and P. Neumann Decision analytic models for Alzheimer's disease: state of the art and future directions Alzheimers Dement 4 2008 212 222 (Pubitemid 351682261)
8. S. Banerjee, and R. Wittenberg Clinical and cost effectiveness of services for early diagnosis and intervention in dementia Int J Geriatr Psych 24 2009 748 754
9. D. Getsios, S. Blume, K.J. Ishak, and G. Maclaine The cost-effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: an updated UK evaluation using discrete event simulation Pharmacoeconomics 28 2010 411 427
10. National Institute for Health and Clinical Excellence (NICE) Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease November 2006 MidCity Mace London Available at: http://www.nice.org.uk
11. E.J. Dasbach, R.P. Insinga, and E.H. Elbasha Cost-utility analysis: a case study of a quadrivalent humn papillomavirus vaccine Renée J.G. Arnold, Pharmacoeconomics: From Theory to Practice 2009 CRC Press Boca Raton, FL 119 132
12. D. Getsios, K. Migliaccio-Walle, and J.J. Caro NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used? Pharmacoeconomics 25 2007 997 1006 (Pubitemid 350208905)
13. CERAD - an overview. Consortium to establish a registry for Alzheimer's disease. Available at: http://cerad.mc.duke.edu/Default.htm. Retrieved March 6, 2009.
14. R.C. Mohs, R.S. Doody, J.C. Morris, J.R. Ieni, S.L. Rogers, and C.A. Perdomo A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients Neurology 57 2001 481 488 (Pubitemid 32757597)
15. B. Winblad, K. Engedal, H. Soininen, F. Verhey, G. Waldemar, and A. Wimo A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD Neurology 57 2001 489 495 (Pubitemid 32757598)
16. H. Feldman, S. Gauthier, J. Hecker, B. Vellas, P. Subbiah, and E.A. Whalen 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease Neurology 57 2001 613 620 (Pubitemid 32782987)
17. S.L. Rogers, M.R. Farlow, R.S. Doody, R. Mohs, L.T. Friedhoff Donepezil Study Group A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease Neurology 50 1998 136 145
18. S.L. Rogers, R.S. Doody, R.C. Mohs, L.T. Friedhoff Donepezil Study Group Donepezil improves cognition and global function in Alzheimer disease: a 15-week, doubleblind, placebo-controlled study Arch Intern Med 158 1998 1021 1031 (Pubitemid 28213580)
19. S.E. Black, R. Doody, H. Li, T. McRae, K.M. Jambor, and Y. Xu Donepezil preserves cognition and global function in patients with severe Alzheimer disease Neurology 69 2007 459 469 (Pubitemid 47450281)
20. B. Winblad, L. Kilander, S. Eriksson, L. Minthon, S. Batsman, and A.L. Wetterholm Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study Lancet 367 2006 1057 1065
21. R.S. Doody, D.S. Geldmacher, B. Gordon, C.A. Perdomo, and R.D. Pratt Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease Arch Neurol 58 2001 427 433 (Pubitemid 32217459)
22. B. Winblad, A. Wimo, K. Engedal, H. Soininen, F. Verhey, and G. Waldemar 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy Dement Geriatr Cogn Disord 21 2006 353 363 (Pubitemid 43735680)
23. S. Lyle, M. Grizzell, S. Willmott, S. Benbow, M. Clark, and D. Jolley Treatment of a whole population sample of Alzheimer's disease with donepezil over a 4-year period: lessons learned Dement Geriatr Cogn Disord 25 2008 226 231 (Pubitemid 351363886)
24. J. Xie, C. Brayne Medical Research Council Cognitive Function and Ageing Study Collaborators Survival time in people with dementia: analysis from population based cohort study with 14 year follow-up BMJ 336 2008 258 262 (Pubitemid 351251626)
25. L. Curtis, and Netten Schema 9.8b General practitioner unit cost. Per clinic consultation lasting 17.2 min. Unit Costs of Health and Social Care 2007 PSSRU Kent, United Kingdom
26. A. Macdonald, and B. Cooper Long-term care dementia services: an impending crisis Age Ageing 36 2007 16 22 (Pubitemid 47072029)
27. Department for business enterprise & regulatory reform. National minimum wage. Available at: http://www.berr.gov.uk/whatwedo/employment/pay/ national-minimum-wage/index.html.
28. L. Jonsson, N. Andreasen, L. Kilander, H. Soininen, G. Waldemar, and H. Nygaard Patient- and proxy-reported utility in Alzheimer disease using the EuroQoL Alzheimer Dis Assoc Disord 20 2006 49 55 (Pubitemid 44356894)
29. J. Bond, C. Stave, A. Sganga, B. O'Connell, and R.L. Stanley Inequalities in dementia care across Europe: key findings of the facing dementia survey Int J Clin Pract 59 Suppl 146 2005 8 14 (Pubitemid 40333120)
30. A.J. Mitchell The clinical significance of subjective memory complaints in the diagnosis of mild cognitive impairment and dementia: a meta-analysis Int J Geriatr Psychiatry 23 2008 1191 1202
31. Department of Health. NHS reference costs 2006-07. Available at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-082571.
32. Department of Health. NHS reference costs 2005-06. Available at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-062884.
33. M.J. Postma Sensitivity analysis J.G. Arnold Renée, Pharmacoeconomics: From Theory to Practice 2009 CRC Press Boca Raton, FL 163 174
34. G. Waldemar, B. Dubois, M. Emre, J. Georges, I.G. McKeith, and M. Rossor Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline Eur J Neurol 14 2007 e1 e26